A massive valuation for a "seed" round can be misleading. Often, insiders have participated in several unannounced, cheaper tranches. The headline number is just the final, most expensive tier, used to create FOMO and set a high watermark for new investors.

The first question in any fundraising or M&A discussion is always, 'What was your last round price?' An inflated number creates psychological friction and can halt negotiations before they begin. Founders should optimize for a valuation that allows for a clear up-round, not just the highest price today.

Accepting too high a valuation can be a fatal error. The first question in any subsequent fundraising or M&A discussion will be about the prior round's price. An unjustifiably high number immediately destroys the psychology of the new deal, making it nearly impossible to raise more capital or sell the company, regardless of progress.

Valuations don't jump dramatically; they 'sneak up on you.' An investor might balk at a $45M cap when they expected $40M. But the fear of missing a potential unicorn is stronger than the desire for a slightly better price, causing a gradual, batch-over-batch inflation of valuation norms.

Anthropic's massive new valuation isn't just a reflection of its success. It's a strategic financial maneuver by late-stage investors to 'anchor' a high price in the market's perception, aiming to maximize value when the company eventually goes public.

Venture rounds are compressing and conflating, with massive "seed" rounds of $30M+ essentially combining a seed and Series A. This sets a dangerous trap: the expectations for your next funding round will be equivalent to those of a traditional Series B company, dramatically raising the bar for growth.

Sequoia sometimes invests in two tranches at different valuations. This allows founders to market the round at the higher valuation, while Sequoia benefits from a lower, blended price. This practice, while common, can mislead employees and other investors about the true deal terms if not properly disclosed.

Chasing high, unrealized valuations is dangerous. It makes common stock prohibitively expensive, undermining the potential for life-changing wealth for employees—a key recruiting tool. It also narrows a company's strategic options, locking it into a high-stakes path where anything less than exceeding the last valuation is seen as failure.

Tranched rounds involve an investor buying shares at two prices (e.g., $250M and $1B) in the same financing. While the investor gets a lower blended cost basis, the company gets to announce the higher valuation. It's a financial engineering tactic that satisfies egos but creates an optics trap.